The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2021 | Waldenström’s therapy: what’s on the horizon?
The future of Waldenström’s macroglobulinemia therapy is bright, with various novel combinations currently under investigation. In this video, Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, delineates what’s on the therapeutic landscape for Waldenström’s. Specifically discussed is the combinatorial use of ibrutinib to achieve deeper responses. For example, ibrutinib is currently being trialed in combination with chemoimmunotherapy, proteasome inhibitors, the CXCR4 inhibitor, EPI-X 4, daratumumab and venetoclax. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.
Disclosures
Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics
